Patent US4264613A successfully refreshed from Google Patents.
US4264613A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Piperidylbenzimidazolinone compounds
Assignee: Science Union et Cie
•
Filing: 1979-08-01
•
Granted: 1981-04-28
•
Expires: 1999-08-01
Abstract
Abstract Piperidylbenzimidazolinone compounds of the formula: ##STR1## in which: R is hydrogen, hydroxy, hydroxymethyl, methoxycarbonyl, formamido, acetamido, mesylamino, oxalamino, ethoxalylamino, carbamoyl ##STR2## ureido ##STR3## or sulfamoylamino ##STR4## in which R' and R" are hydrogen or lower alkyl, T is hydrogen, halogen, lower alkyl or lower alkoxy, and Z is hydrogen, lower alkyl or lower alkenyl each in straight or branched chain. These compounds and physiologically tolerable acid addition salts thereof may be used as medicines especially in the treatment of autoimmune, allergic and inflammatory diseases and in the treatment of respiratory insufficiency of asthma.
Inventors
- 👤 Gilbert Regnier
- 👤 Alain Dhainaut
- 👤 Jacques Duhault
- 👤 Michelle Boulanger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 21:36
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/04
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
136 words
A compound selected from the group consisting of: piperidylbenzimidazolinone compounds of the formula: ##STR18## in which: R is selected from the group consisting of hydrogen, hydroxy (OH--), hydroxymethyl (HO--CH 2 --), formamido (H--CO--NH--), acetamido (CH 3 --CO--NH--), mesylamino (CH 3 --SO 2 --NH--), oxalamino (HOOC--CO--NH--), ethoxalylamino (C 2 H 5 OOC--CO--NH--), ureido ##STR19## and sulfamoylamino ##STR20## R' and R", being identical or different, are each selected from the group consisting of hydrogen and alkyl having from 1 to 5 carbon atoms inclusive, T is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy each having from 1 to 5 carbon atoms inclusive, and Z is selected from the group consisting of hydrogen, alkyl and alkenyl each having from 1 to 5 carbon atoms inclusive in straight and branched chain; and physiologically tolerable salts thereof.
Claim 2
Dependent Claim
136 words
A compound selected from the group consisting of: piperidylbenzimidazolinone compounds of the formula: ##STR18## in which: R is selected from the group consisting of hydrogen, hydroxy (OH--), hydroxymethyl (HO--CH 2 --), formamido (H--CO--NH--), acetamido (CH 3 --CO--NH--), mesylamino (CH 3 --SO 2 --NH--), oxalamino (HOOC--CO--NH--), ethoxalylamino (C 2 H 5 OOC--CO--NH--), ureido ##STR19## and sulfamoylamino ##STR20## R' and R", being identical or different, are each selected from the group consisting of hydrogen and alkyl having from 1 to 5 carbon atoms inclusive, T is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy each having from 1 to 5 carbon atoms inclusive, and Z is selected from the group consisting of hydrogen, alkyl and alkenyl each having from 1 to 5 carbon atoms inclusive in straight and branched chain; and physiologically tolerable salts thereof.
Claim 3
Dependent Claim
8 words
A compound of claim 1 which is 1-[2-(3,4-dihydroxyphenyl)-2-hydroxy]ethyl-4-(2-oxobenzimidazolin-1-yl)piperidine.
Claim 4
Dependent Claim
8 words
A compound of claim 1 which is 1-[2-(4-hydroxyphenyl)-2-hydroxy]ethyl-4-(2-oxobenzimidazolin-1-yl)piperidine.
Claim 5
Dependent Claim
11 words
A compound of claim 1 which is 1-[2-(3,5-dihydroxyphenyl)-2-hydroxy]ethyl-4-(2-oxobenzimidazolin-1-yl)piperidine and its hydrochloride.
Claim 6
Dependent Claim
29 words
A pharmaceutical composition having broncodilating, β-adrenergic and anti-allergic activity containing an effective amount of a compound of claim 1 as active ingredient, together with a suitable physiologically acceptable carrier.
Claim 7
Dependent Claim
41 words
A method for treating a living animal body afflicted with antoimmune allergic or anti-inflammatory diseases or asthmatic dyspnea, comprising the step of administering an amount of a compound of claim 1 which is effective for the alleviation of the said condition.
References Cited (Backward Citations)
US3196157A
Cited
US3318900A
Cited
US4080328A
Cited
US3818017A
Cited
US3894030A
Cited
US3929801A
Cited
US4200755A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-04-27 | 1984-10-27 | 1985-04-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-04-27 | 1988-10-27 | 1989-04-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-04-27 | 1992-10-27 | 1993-04-28 | $7700.00 | Window Closed / Lapsed |